IBBQ holdings
Invesco Nasdaq Biotechnology ETF
Positions
261 stored of 261 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | Not reported | Not reported | 14.204% | $9.6M | Short-term investment vehicles (cash funds) | Private fund | United States | USD |
| 2 | Gilead Sciences, Inc. | US3755581036 | 375558103 | 7.390% | $5.0M | Equity (common) | Corporate | United States | USD |
| 3 | Vertex Pharmaceuticals Inc. | US92532F1003 | 92532F100 | 7.376% | $5.0M | Equity (common) | Corporate | United States | USD |
| 4 | Amgen Inc. | US0311621009 | 031162100 | 7.105% | $4.8M | Equity (common) | Corporate | United States | USD |
| 5 | Invesco Private Government Fund | Not reported | Not reported | 5.479% | $3.7M | Short-term investment vehicles (cash funds) | Private fund | United States | USD |
| 6 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 75886F107 | 5.083% | $3.4M | Equity (common) | Corporate | United States | USD |
| 7 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 02043Q107 | 3.187% | $2.1M | Equity (common) | Corporate | United States | USD |
| 8 | Revolution Medicines, Inc. | US76155X1000 | 76155X100 | 2.483% | $1.7M | Equity (common) | Corporate | United States | USD |
| 9 | Biogen Inc. | US09062X1037 | 09062X103 | 2.289% | $1.5M | Equity (common) | Corporate | United States | USD |
| 10 | Illumina, Inc. | US4523271090 | 452327109 | 1.983% | $1.3M | Equity (common) | Corporate | United States | USD |
| 11 | United Therapeutics Corp. | US91307C1027 | 91307C102 | 1.942% | $1.3M | Equity (common) | Corporate | United States | USD |
| 12 | Royalty Pharma PLC Royalty Pharma PLC, Class A | GB00BMVP7Y09 | G7709Q104 | 1.901% | $1.3M | Equity (common) | Corporate | United Kingdom | USD |
| 13 | argenx SE argenx SE, ADR | US04016X1019 | 04016X101 | 1.887% | $1.3M | Equity (common) | Corporate | Netherlands | USD |
| 14 | Insmed Inc. | US4576693075 | 457669307 | 1.834% | $1.2M | Equity (common) | Corporate | United States | USD |
| 15 | Roivant Sciences Ltd. | BMG762791017 | G76279101 | 1.708% | $1.2M | Equity (common) | Corporate | Bermuda | USD |
| 16 | Incyte Corp. | US45337C1027 | 45337C102 | 1.532% | $1.0M | Equity (common) | Corporate | United States | USD |
| 17 | Viatris Inc. | US92556V1061 | 92556V106 | 1.490% | $1.0M | Equity (common) | Corporate | United States | USD |
| 18 | Moderna, Inc. | US60770K1079 | 60770K107 | 1.483% | $999K | Equity (common) | Corporate | United States | USD |
| 19 | Guardant Health, Inc. | US40131M1099 | 40131M109 | 1.354% | $912K | Equity (common) | Corporate | United States | USD |
| 20 | Neurocrine Biosciences, Inc. | US64125C1099 | 64125C109 | 1.264% | $852K | Equity (common) | Corporate | United States | USD |
| 21 | Jazz Pharmaceuticals PLC | IE00B4Q5ZN47 | G50871105 | 1.158% | $780K | Equity (common) | Corporate | Ireland | USD |
| 22 | Ascendis Pharma A/S | DK0060615755 | K08588103 | 1.098% | $740K | Equity (common) | Corporate | Denmark | USD |
| 23 | Summit Therapeutics Inc. | US86627T1088 | 86627T108 | 1.082% | $729K | Equity (common) | Corporate | United States | USD |
| 24 | Exelixis, Inc. | US30161Q1040 | 30161Q104 | 1.043% | $703K | Equity (common) | Corporate | United States | USD |
| 25 | BridgeBio Pharma, Inc. | US10806X1028 | 10806X102 | 1.022% | $689K | Equity (common) | Corporate | United States | USD |
| 26 | Medpace Holdings, Inc. | US58506Q1094 | 58506Q109 | 1.010% | $681K | Equity (common) | Corporate | United States | USD |
| 27 | Ionis Pharmaceuticals, Inc. | US4622221004 | 462222100 | 1.006% | $677K | Equity (common) | Corporate | United States | USD |
| 28 | Axsome Therapeutics, Inc. | US05464T1043 | 05464T104 | 0.954% | $643K | Equity (common) | Corporate | United States | USD |
| 29 | Madrigal Pharmaceuticals, Inc. | US5588681057 | 558868105 | 0.908% | $612K | Equity (common) | Corporate | United States | USD |
| 30 | BioMarin Pharmaceutical Inc. | US09061G1013 | 09061G101 | 0.877% | $591K | Equity (common) | Corporate | United States | USD |
| 31 | BioNTech SE BioNTech SE, ADR | US09075V1026 | 09075V102 | 0.870% | $586K | Equity (common) | Corporate | Germany | USD |
| 32 | Arrowhead Pharmaceuticals, Inc. | US04280A1007 | 04280A100 | 0.868% | $585K | Equity (common) | Corporate | United States | USD |
| 33 | Sanofi Sanofi, ADR | US80105N1054 | 80105N105 | 0.851% | $573K | Equity (common) | Corporate | France | USD |
| 34 | Praxis Precision Medicines, Inc. | US74006W2070 | 74006W207 | 0.776% | $523K | Equity (common) | Corporate | United States | USD |
| 35 | Cytokinetics, Inc. | US23282W6057 | 23282W605 | 0.752% | $506K | Equity (common) | Corporate | United States | USD |
| 36 | BeOne Medicines Ltd. BeOne Medicines Ltd., ADR | US07725L1026 | 07725L102 | 0.732% | $493K | Equity (common) | Corporate | Switzerland | USD |
| 37 | Krystal Biotech, Inc. | US5011471027 | 501147102 | 0.719% | $484K | Equity (common) | Corporate | United States | USD |
| 38 | Tempus AI, Inc. Tempus AI, Inc., Class A | US88023B1035 | 88023B103 | 0.698% | $470K | Equity (common) | Corporate | United States | USD |
| 39 | Abivax S.A. Abivax S.A., ADR | US00370M1036 | 00370M103 | 0.648% | $437K | Equity (common) | Corporate | France | USD |
| 40 | Nuvalent, Inc. Nuvalent, Inc., Class A | US6707031075 | 670703107 | 0.643% | $433K | Equity (common) | Corporate | United States | USD |
| 41 | Halozyme Therapeutics, Inc. | US40637H1095 | 40637H109 | 0.625% | $421K | Equity (common) | Corporate | United States | USD |
| 42 | ImmunityBio, Inc. | US45256X1037 | 45256X103 | 0.615% | $414K | Equity (common) | Corporate | United States | USD |
| 43 | Vaxcyte, Inc. | US92243G1085 | 92243G108 | 0.589% | $397K | Equity (common) | Corporate | United States | USD |
| 44 | Alkermes PLC | IE00B56GVS15 | G01767105 | 0.559% | $377K | Equity (common) | Corporate | Ireland | USD |
| 45 | Immunovant, Inc. | US45258J1025 | 45258J102 | 0.539% | $363K | Equity (common) | Corporate | United States | USD |
| 46 | Kymera Therapeutics, Inc. | US5015751044 | 501575104 | 0.529% | $356K | Equity (common) | Corporate | United States | USD |
| 47 | Protagonist Therapeutics, Inc. | US74366E1029 | 74366E102 | 0.506% | $341K | Equity (common) | Corporate | United States | USD |
| 48 | Mirum Pharmaceuticals, Inc. | US6047491013 | 604749101 | 0.487% | $328K | Equity (common) | Corporate | United States | USD |
| 49 | PTC Therapeutics, Inc. | US69366J2006 | 69366J200 | 0.486% | $327K | Equity (common) | Corporate | United States | USD |
| 50 | Rhythm Pharmaceuticals, Inc. | US76243J1051 | 76243J105 | 0.480% | $323K | Equity (common) | Corporate | United States | USD |
| 51 | Spyre Therapeutics, Inc. | US00773J2024 | 00773J202 | 0.459% | $309K | Equity (common) | Corporate | United States | USD |
| 52 | Cogent Biosciences, Inc. | US19240Q2012 | 19240Q201 | 0.452% | $304K | Equity (common) | Corporate | United States | USD |
| 53 | CRISPR Therapeutics AG | CH0334081137 | H17182108 | 0.428% | $289K | Equity (common) | Corporate | Switzerland | USD |
| 54 | CG Oncology, Inc. | US1569441009 | 156944100 | 0.419% | $282K | Equity (common) | Corporate | United States | USD |
| 55 | Scholar Rock Holding Corp. | US80706P1030 | 80706P103 | 0.399% | $269K | Equity (common) | Corporate | United States | USD |
| 56 | Centessa Pharmaceuticals PLC Centessa Pharmaceuticals PLC, ADR | US1523091007 | 152309100 | 0.378% | $255K | Equity (common) | Corporate | United Kingdom | USD |
| 57 | Caris Life Sciences, Inc. | US1421521071 | 142152107 | 0.375% | $252K | Equity (common) | Corporate | United States | USD |
| 58 | Ligand Pharmaceuticals Inc. | US53220K5048 | 53220K504 | 0.368% | $248K | Equity (common) | Corporate | United States | USD |
| 59 | Xenon Pharmaceuticals Inc. | CA98420N1050 | 98420N105 | 0.362% | $244K | Equity (common) | Corporate | Canada | USD |
| 60 | Indivior Pharmaceuticals, Inc. | US45579U1097 | 45579U109 | 0.358% | $241K | Equity (common) | Corporate | United States | USD |
| 61 | Apogee Therapeutics, Inc. | US03770N1019 | 03770N101 | 0.358% | $241K | Equity (common) | Corporate | United States | USD |
| 62 | Travere Therapeutics, Inc. | US89422G1076 | 89422G107 | 0.346% | $233K | Equity (common) | Corporate | United States | USD |
| 63 | Amneal Pharmaceuticals, Inc. | US03168L1052 | 03168L105 | 0.330% | $222K | Equity (common) | Corporate | United States | USD |
| 64 | Twist Bioscience Corp. | US90184D1000 | 90184D100 | 0.326% | $220K | Equity (common) | Corporate | United States | USD |
| 65 | Erasca, Inc. | US29479A1088 | 29479A108 | 0.316% | $213K | Equity (common) | Corporate | United States | USD |
| 66 | NewAmsterdam Pharma Co. N.V. | NL00150012L7 | N62509109 | 0.308% | $208K | Equity (common) | Corporate | Netherlands | USD |
| 67 | Crinetics Pharmaceuticals, Inc. | US22663K1079 | 22663K107 | 0.296% | $200K | Equity (common) | Corporate | United States | USD |
| 68 | Acadia Pharmaceuticals Inc. | US0042251084 | 004225108 | 0.294% | $198K | Equity (common) | Corporate | United States | USD |
| 69 | Veracyte, Inc. | US92337F1075 | 92337F107 | 0.293% | $197K | Equity (common) | Corporate | United States | USD |
| 70 | Edgewise Therapeutics, Inc. | US28036F1057 | 28036F105 | 0.292% | $196K | Equity (common) | Corporate | United States | USD |
| 71 | Beam Therapeutics Inc. | US07373V1052 | 07373V105 | 0.267% | $180K | Equity (common) | Corporate | United States | USD |
| 72 | Denali Therapeutics Inc. | US24823R1059 | 24823R105 | 0.266% | $179K | Equity (common) | Corporate | United States | USD |
| 73 | 10x Genomics, Inc. 10x Genomics, Inc., Class A | US88025U1097 | 88025U109 | 0.265% | $179K | Equity (common) | Corporate | United States | USD |
| 74 | Dyne Therapeutics, Inc. | US26818M1080 | 26818M108 | 0.253% | $171K | Equity (common) | Corporate | United States | USD |
| 75 | Structure Therapeutics Inc. Structure Therapeutics Inc., ADR | US86366E1064 | 86366E106 | 0.244% | $164K | Equity (common) | Corporate | Cayman Islands | USD |
| 76 | Tango Therapeutics Inc. | US87583X1090 | 87583X109 | 0.236% | $159K | Equity (common) | Corporate | United States | USD |
| 77 | Oruka Therapeutics, Inc. | US6876041087 | 687604108 | 0.225% | $152K | Equity (common) | Corporate | United States | USD |
| 78 | GRAIL, Inc. | US3847471014 | 384747101 | 0.223% | $150K | Equity (common) | Corporate | United States | USD |
| 79 | Alumis Inc. | US0223071020 | 022307102 | 0.217% | $146K | Equity (common) | Corporate | United States | USD |
| 80 | Arcutis Biotherapeutics, Inc. | US03969K1088 | 03969K108 | 0.212% | $143K | Equity (common) | Corporate | United States | USD |
| 81 | Disc Medicine, Inc. | US2546041011 | 254604101 | 0.211% | $142K | Equity (common) | Corporate | United States | USD |
| 82 | Supernus Pharmaceuticals, Inc. | US8684591089 | 868459108 | 0.211% | $142K | Equity (common) | Corporate | United States | USD |
| 83 | IDEAYA Biosciences, Inc. | US45166A1025 | 45166A102 | 0.206% | $139K | Equity (common) | Corporate | United States | USD |
| 84 | Vera Therapeutics, Inc. | US92337R1014 | 92337R101 | 0.202% | $136K | Equity (common) | Corporate | United States | USD |
| 85 | Tarsus Pharmaceuticals, Inc. | US87650L1035 | 87650L103 | 0.201% | $136K | Equity (common) | Corporate | United States | USD |
| 86 | Relay Therapeutics, Inc. | US75943R1023 | 75943R102 | 0.200% | $135K | Equity (common) | Corporate | United States | USD |
| 87 | Mineralys Therapeutics, Inc. | US6031701013 | 603170101 | 0.198% | $134K | Equity (common) | Corporate | United States | USD |
| 88 | Definium Therapeutics, Inc. | CA24477V1058 | 24477V105 | 0.192% | $129K | Equity (common) | Corporate | Canada | USD |
| 89 | Enliven Therapeutics, Inc. | US29337E1029 | 29337E102 | 0.187% | $126K | Equity (common) | Corporate | United States | USD |
| 90 | Adaptive Biotechnologies Corp. | US00650F1093 | 00650F109 | 0.186% | $125K | Equity (common) | Corporate | United States | USD |
| 91 | Ultragenyx Pharmaceutical Inc. | US90400D1081 | 90400D108 | 0.184% | $124K | Equity (common) | Corporate | United States | USD |
| 92 | Legend Biotech Corp. Legend Biotech Corp., ADR | US52490G1022 | 52490G102 | 0.182% | $123K | Equity (common) | Corporate | Cayman Islands | USD |
| 93 | Kodiak Sciences Inc. | US50015M1099 | 50015M109 | 0.178% | $120K | Equity (common) | Corporate | United States | USD |
| 94 | BioCryst Pharmaceuticals, Inc. | US09058V1035 | 09058V103 | 0.178% | $120K | Equity (common) | Corporate | United States | USD |
| 95 | Kiniksa Pharmaceuticals International, PLC | GB00BRXB0C07 | G52694109 | 0.177% | $119K | Equity (common) | Corporate | United Kingdom | USD |
| 96 | Aurinia Pharmaceuticals Inc. | CA05156V1022 | 05156V102 | 0.162% | $109K | Equity (common) | Corporate | Canada | USD |
| 97 | Ocular Therapeutix, Inc. | US67576A1007 | 67576A100 | 0.156% | $105K | Equity (common) | Corporate | United States | USD |
| 98 | Pharvaris N.V. | NL00150005Y4 | N69605108 | 0.154% | $104K | Equity (common) | Corporate | Netherlands | USD |
| 99 | NovoCure Ltd. | JE00BYSS4X48 | G6674U108 | 0.154% | $103K | Equity (common) | Corporate | Jersey | USD |
| 100 | Sionna Therapeutics, Inc. | US8294011080 | 829401108 | 0.152% | $102K | Equity (common) | Corporate | United States | USD |